Limits...
Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.

Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H - Res Pharm Sci (2015 Mar-Apr)

Bottom Line: Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition.WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells.Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin.

View Article: PubMed Central - PubMed

Affiliation: Department of pharmaceutical biotechnology and Isfahan Pharmaceutical Sciences Research Centre, School of pharmacy and pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

ABSTRACT
Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition. However their exact role in tumor development is not yet fully unraveled. MSCs were established to perform many of their actions through paracrine effect. Thus investigation of MSC secretome interaction with tumor cells may provide important information for scientists who are attempting to apply stem cells in the treatment of the disease. In this study we investigated the effect of human Wharton's jelly derived MSC (WJ-MSCs) secretome on proliferation, apoptotic potential of A549 lung cancer cells, and their response to the chemotherapeutic agent doxorubicin. WJ-MSCs were isolated from human umbilical cord and then characterized according to the International Society for Cellular Therapy criteria and WJ-MSC secretome was collected. BrdU cell proliferation assay and Annexin V-PI staining were used for the evaluation of cytotoxic and proapoptotic effects of WJ-MSC secretome on A549 cells. WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells. We also studied the combinatorial effect of WJ-MSC secretome and the anticancer drug doxorubicinwhich showed no induction of drug resistance when A549 cells was treated with combination of WJ-MSC secretome and doxorubicin. Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin. Thus MSC secretome could be considered safe for other medical purposes such as cardiovascular, neurodegenerative, and autoimmune diseases which may exist or occur in cancer patients.

No MeSH data available.


Related in: MedlinePlus

BrdU proliferation assay. a; A549 cell proliferation did not change significantly before and after treatment with hWJ-MSC secretome (obtained from intact MSCs or IFNγ stimulated MSCs), b; WJ-MSC secretome did not induce resistance to doxorubicin in A549 cells because A549 cell proliferation did not change significantly when treated by doxorubicin alone or doxorubicin + hWJ-MSC secretom or doxorubicin + IFNγ stimulated hWJMSC secretome.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4584452&req=5

Figure 4: BrdU proliferation assay. a; A549 cell proliferation did not change significantly before and after treatment with hWJ-MSC secretome (obtained from intact MSCs or IFNγ stimulated MSCs), b; WJ-MSC secretome did not induce resistance to doxorubicin in A549 cells because A549 cell proliferation did not change significantly when treated by doxorubicin alone or doxorubicin + hWJ-MSC secretom or doxorubicin + IFNγ stimulated hWJMSC secretome.

Mentions: A549 cells were treated with WJ-MSC secretome for 72 h, and cell proliferation was evaluated by BrdU incorporation assay. Results showed that WJ-MSC secretome did not proliferate differently from untreated cells (P>0.05). Cancer cells growth which were treated with MSC sec was 104.59% ± 0.044 compared to untreated cells (Fig. 4a).


Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.

Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H - Res Pharm Sci (2015 Mar-Apr)

BrdU proliferation assay. a; A549 cell proliferation did not change significantly before and after treatment with hWJ-MSC secretome (obtained from intact MSCs or IFNγ stimulated MSCs), b; WJ-MSC secretome did not induce resistance to doxorubicin in A549 cells because A549 cell proliferation did not change significantly when treated by doxorubicin alone or doxorubicin + hWJ-MSC secretom or doxorubicin + IFNγ stimulated hWJMSC secretome.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4584452&req=5

Figure 4: BrdU proliferation assay. a; A549 cell proliferation did not change significantly before and after treatment with hWJ-MSC secretome (obtained from intact MSCs or IFNγ stimulated MSCs), b; WJ-MSC secretome did not induce resistance to doxorubicin in A549 cells because A549 cell proliferation did not change significantly when treated by doxorubicin alone or doxorubicin + hWJ-MSC secretom or doxorubicin + IFNγ stimulated hWJMSC secretome.
Mentions: A549 cells were treated with WJ-MSC secretome for 72 h, and cell proliferation was evaluated by BrdU incorporation assay. Results showed that WJ-MSC secretome did not proliferate differently from untreated cells (P>0.05). Cancer cells growth which were treated with MSC sec was 104.59% ± 0.044 compared to untreated cells (Fig. 4a).

Bottom Line: Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition.WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells.Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin.

View Article: PubMed Central - PubMed

Affiliation: Department of pharmaceutical biotechnology and Isfahan Pharmaceutical Sciences Research Centre, School of pharmacy and pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

ABSTRACT
Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition. However their exact role in tumor development is not yet fully unraveled. MSCs were established to perform many of their actions through paracrine effect. Thus investigation of MSC secretome interaction with tumor cells may provide important information for scientists who are attempting to apply stem cells in the treatment of the disease. In this study we investigated the effect of human Wharton's jelly derived MSC (WJ-MSCs) secretome on proliferation, apoptotic potential of A549 lung cancer cells, and their response to the chemotherapeutic agent doxorubicin. WJ-MSCs were isolated from human umbilical cord and then characterized according to the International Society for Cellular Therapy criteria and WJ-MSC secretome was collected. BrdU cell proliferation assay and Annexin V-PI staining were used for the evaluation of cytotoxic and proapoptotic effects of WJ-MSC secretome on A549 cells. WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells. We also studied the combinatorial effect of WJ-MSC secretome and the anticancer drug doxorubicinwhich showed no induction of drug resistance when A549 cells was treated with combination of WJ-MSC secretome and doxorubicin. Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin. Thus MSC secretome could be considered safe for other medical purposes such as cardiovascular, neurodegenerative, and autoimmune diseases which may exist or occur in cancer patients.

No MeSH data available.


Related in: MedlinePlus